Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing

$877,086R01FY2021HLNIH

Fred Hutchinson Cancer Center, Seattle WA

Investigators

Roland Bruno Waltercontact Hans-Peter Kiem

Linked publications, trials & patents

Paper 37951207 Paper 34601132

View original record on NIH RePORTER →

Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing · GrantIndex